Beam Therapeutics Inc (BEAM)
22.54
-0.24
(-1.05%)
USD |
NASDAQ |
May 07, 16:00
22.40
-0.14
(-0.62%)
After-Hours: 20:00
Beam Therapeutics Enterprise Value: 670.29M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 06, 2024 | 670.29M |
May 03, 2024 | 698.87M |
May 02, 2024 | 665.39M |
May 01, 2024 | 585.36M |
April 30, 2024 | 542.90M |
April 29, 2024 | 610.68M |
April 26, 2024 | 555.97M |
April 25, 2024 | 573.93M |
April 24, 2024 | 667.02M |
April 23, 2024 | 726.63M |
April 22, 2024 | 778.07M |
April 19, 2024 | 761.74M |
April 18, 2024 | 795.22M |
April 17, 2024 | 795.22M |
April 16, 2024 | 908.73M |
April 15, 2024 | 908.73M |
April 12, 2024 | 927.51M |
April 11, 2024 | 1.037B |
April 10, 2024 | 1.020B |
April 09, 2024 | 1.204B |
April 08, 2024 | 1.163B |
April 05, 2024 | 1.113B |
April 04, 2024 | 1.181B |
April 03, 2024 | 1.234B |
April 02, 2024 | 1.305B |
Date | Value |
---|---|
April 01, 2024 | 1.477B |
March 28, 2024 | 1.508B |
March 27, 2024 | 1.583B |
March 26, 2024 | 1.523B |
March 25, 2024 | 1.561B |
March 22, 2024 | 1.556B |
March 21, 2024 | 1.664B |
March 20, 2024 | 1.658B |
March 19, 2024 | 1.655B |
March 18, 2024 | 1.592B |
March 15, 2024 | 1.702B |
March 14, 2024 | 1.636B |
March 13, 2024 | 1.862B |
March 12, 2024 | 1.733B |
March 11, 2024 | 1.796B |
March 08, 2024 | 1.875B |
March 07, 2024 | 1.828B |
March 06, 2024 | 1.936B |
March 05, 2024 | 1.955B |
March 04, 2024 | 1.933B |
March 01, 2024 | 2.063B |
February 29, 2024 | 2.035B |
February 28, 2024 | 2.371B |
February 27, 2024 | 2.490B |
February 26, 2024 | 1.733B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
388.81M
Minimum
Oct 20 2023
7.996B
Maximum
Jul 01 2021
2.526B
Average
1.765B
Median
Enterprise Value Benchmarks
Eli Lilly and Co | 752.37B |
Moderna Inc | 38.29B |
Editas Medicine Inc | 140.77M |
Intellia Therapeutics Inc | 1.367B |
Perspective Therapeutics Inc | 1.067B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 142.80M |
Revenue (Quarterly) | 316.19M |
Total Expenses (Quarterly) | 183.33M |
EPS Diluted (Quarterly) | 1.73 |
Profit Margin (Quarterly) | 45.16% |
Earnings Yield | -8.43% |
Normalized Earnings Yield | -8.330 |